CRISPR Therapeutics AG·4

Oct 12, 5:41 PM ET

Morrow Phuong Khanh 4

4 · CRISPR Therapeutics AG · Filed Oct 12, 2022

Insider Transaction Report

Form 4
Period: 2022-10-07
Morrow Phuong Khanh
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-10-07+9,3809,380 total
    Exercise: $61.65Exp: 2032-10-07Common Shares (9,380 underlying)
Footnotes (1)
  • [F1]This option was granted on October 7, 2022 with respect to 9,380 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION